<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints — optimal_multiple_normal • drugdevelopR</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet"><link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet"><script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints — optimal_multiple_normal"><meta name="description" content="The function optimal_multiple_normal of the drugdevelopR
package enables planning of phase II/III drug development programs with
optimal sample size allocation and go/no-go decision rules for two-arm
trials with two normally  distributed endpoints and one control group
(Preussler et. al, 2019)."><meta property="og:description" content="The function optimal_multiple_normal of the drugdevelopR
package enables planning of phase II/III drug development programs with
optimal sample size allocation and go/no-go decision rules for two-arm
trials with two normally  distributed endpoints and one control group
(Preussler et. al, 2019)."></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top bg-light" data-bs-theme="light" aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.0.2</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item"><a class="nav-link" href="../reference/index.html">Reference</a></li>
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-articles" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Articles</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-articles"><li><a class="dropdown-item" href="../articles/Introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a></li>
    <li><a class="dropdown-item" href="../articles/Package_validation.html">Package validation</a></li>
    <li><hr class="dropdown-divider"></li>
    <li><a class="dropdown-item" href="../articles/index.html">More articles...</a></li>
  </ul></li>
<li class="nav-item"><a class="nav-link" href="../news/index.html">Changelog</a></li>
      </ul><ul class="navbar-nav"><li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json"></form></li>
<li class="nav-item"><a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="GitHub"><span class="fa fab fa-github fa-lg"></span></a></li>
      </ul></div>


  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">

      <h1>Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints</h1>
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/R/optimal_multiple_normal.R" class="external-link"><code>R/optimal_multiple_normal.R</code></a></small>
      <div class="d-none name"><code>optimal_multiple_normal.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>The function <code>optimal_multiple_normal</code> of the drugdevelopR
package enables planning of phase II/III drug development programs with
optimal sample size allocation and go/no-go decision rules for two-arm
trials with two normally  distributed endpoints and one control group
(Preussler et. al, 2019).</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">optimal_multiple_normal</span><span class="op">(</span></span>
<span>  <span class="va">Delta1</span>,</span>
<span>  <span class="va">Delta2</span>,</span>
<span>  <span class="va">in1</span>,</span>
<span>  <span class="va">in2</span>,</span>
<span>  <span class="va">sigma1</span>,</span>
<span>  <span class="va">sigma2</span>,</span>
<span>  <span class="va">n2min</span>,</span>
<span>  <span class="va">n2max</span>,</span>
<span>  <span class="va">stepn2</span>,</span>
<span>  <span class="va">kappamin</span>,</span>
<span>  <span class="va">kappamax</span>,</span>
<span>  <span class="va">stepkappa</span>,</span>
<span>  <span class="va">alpha</span>,</span>
<span>  <span class="va">beta</span>,</span>
<span>  <span class="va">c2</span>,</span>
<span>  <span class="va">c3</span>,</span>
<span>  <span class="va">c02</span>,</span>
<span>  <span class="va">c03</span>,</span>
<span>  K <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  N <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,</span>
<span>  steps1 <span class="op">=</span> <span class="fl">0</span>,</span>
<span>  stepm1 <span class="op">=</span> <span class="fl">0.5</span>,</span>
<span>  stepl1 <span class="op">=</span> <span class="fl">0.8</span>,</span>
<span>  <span class="va">b1</span>,</span>
<span>  <span class="va">b2</span>,</span>
<span>  <span class="va">b3</span>,</span>
<span>  <span class="va">rho</span>,</span>
<span>  <span class="va">fixed</span>,</span>
<span>  relaxed <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  num_cl <span class="op">=</span> <span class="fl">1</span></span>
<span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>


<dl><dt id="arg-delta-">Delta1<a class="anchor" aria-label="anchor" href="#arg-delta-"></a></dt>
<dd><p>assumed true treatment effect for endpoint 1 measured as the
difference in means</p></dd>


<dt id="arg-delta-">Delta2<a class="anchor" aria-label="anchor" href="#arg-delta-"></a></dt>
<dd><p>assumed true treatment effect for endpoint 2 measured as the
difference in means</p></dd>


<dt id="arg-in-">in1<a class="anchor" aria-label="anchor" href="#arg-in-"></a></dt>
<dd><p>amount of information for Delta1 in terms of number of events</p></dd>


<dt id="arg-in-">in2<a class="anchor" aria-label="anchor" href="#arg-in-"></a></dt>
<dd><p>amount of information for Delta2 in terms of number of events</p></dd>


<dt id="arg-sigma-">sigma1<a class="anchor" aria-label="anchor" href="#arg-sigma-"></a></dt>
<dd><p>variance of endpoint 1</p></dd>


<dt id="arg-sigma-">sigma2<a class="anchor" aria-label="anchor" href="#arg-sigma-"></a></dt>
<dd><p>variance of endpoint 2</p></dd>


<dt id="arg-n-min">n2min<a class="anchor" aria-label="anchor" href="#arg-n-min"></a></dt>
<dd><p>minimal total sample size in phase II, must be divisible by 3</p></dd>


<dt id="arg-n-max">n2max<a class="anchor" aria-label="anchor" href="#arg-n-max"></a></dt>
<dd><p>maximal total sample size in phase II, must be divisible by 3</p></dd>


<dt id="arg-stepn-">stepn2<a class="anchor" aria-label="anchor" href="#arg-stepn-"></a></dt>
<dd><p>stepsize for the optimization over n2, must be divisible by 3</p></dd>


<dt id="arg-kappamin">kappamin<a class="anchor" aria-label="anchor" href="#arg-kappamin"></a></dt>
<dd><p>minimal threshold value kappa for the go/no-go decision rule</p></dd>


<dt id="arg-kappamax">kappamax<a class="anchor" aria-label="anchor" href="#arg-kappamax"></a></dt>
<dd><p>maximal threshold value  kappa for the go/no-go decision rule</p></dd>


<dt id="arg-stepkappa">stepkappa<a class="anchor" aria-label="anchor" href="#arg-stepkappa"></a></dt>
<dd><p>step size for the optimization over the threshold value kappa</p></dd>


<dt id="arg-alpha">alpha<a class="anchor" aria-label="anchor" href="#arg-alpha"></a></dt>
<dd><p>one-sided significance level/family-wise error rate</p></dd>


<dt id="arg-beta">beta<a class="anchor" aria-label="anchor" href="#arg-beta"></a></dt>
<dd><p>type-II error rate for any pair, i.e. <code>1 - beta</code> is the (any-pair) power for calculation of the sample size for phase III</p></dd>


<dt id="arg-c-">c2<a class="anchor" aria-label="anchor" href="#arg-c-"></a></dt>
<dd><p>variable per-patient cost for phase II in 10^5 $</p></dd>


<dt id="arg-c-">c3<a class="anchor" aria-label="anchor" href="#arg-c-"></a></dt>
<dd><p>variable per-patient cost for phase III in 10^5 $</p></dd>


<dt id="arg-c-">c02<a class="anchor" aria-label="anchor" href="#arg-c-"></a></dt>
<dd><p>fixed cost for phase II in 10^5 $</p></dd>


<dt id="arg-c-">c03<a class="anchor" aria-label="anchor" href="#arg-c-"></a></dt>
<dd><p>fixed cost for phase III in 10^5 $</p></dd>


<dt id="arg-k">K<a class="anchor" aria-label="anchor" href="#arg-k"></a></dt>
<dd><p>constraint on the costs of the program, default: Inf, e.g. no constraint</p></dd>


<dt id="arg-n">N<a class="anchor" aria-label="anchor" href="#arg-n"></a></dt>
<dd><p>constraint on the total expected sample size of the program, default: Inf, e.g. no constraint</p></dd>


<dt id="arg-s">S<a class="anchor" aria-label="anchor" href="#arg-s"></a></dt>
<dd><p>constraint on the expected probability of a successful program, default: -Inf, e.g. no constraint</p></dd>


<dt id="arg-steps-">steps1<a class="anchor" aria-label="anchor" href="#arg-steps-"></a></dt>
<dd><p>lower boundary for effect size category "small", default: 0</p></dd>


<dt id="arg-stepm-">stepm1<a class="anchor" aria-label="anchor" href="#arg-stepm-"></a></dt>
<dd><p>lower boundary for effect size category "medium" = upper boundary for effect size category "small" default: 0.5</p></dd>


<dt id="arg-stepl-">stepl1<a class="anchor" aria-label="anchor" href="#arg-stepl-"></a></dt>
<dd><p>lower boundary for effect size category "large" = upper boundary for effect size category "medium", default: 0.8</p></dd>


<dt id="arg-b-">b1<a class="anchor" aria-label="anchor" href="#arg-b-"></a></dt>
<dd><p>expected gain for effect size category "small" in 10^5 $</p></dd>


<dt id="arg-b-">b2<a class="anchor" aria-label="anchor" href="#arg-b-"></a></dt>
<dd><p>expected gain for effect size category "medium" in 10^5 $</p></dd>


<dt id="arg-b-">b3<a class="anchor" aria-label="anchor" href="#arg-b-"></a></dt>
<dd><p>expected gain for effect size category "large" in 10^5 $</p></dd>


<dt id="arg-rho">rho<a class="anchor" aria-label="anchor" href="#arg-rho"></a></dt>
<dd><p>correlation between the two endpoints</p></dd>


<dt id="arg-fixed">fixed<a class="anchor" aria-label="anchor" href="#arg-fixed"></a></dt>
<dd><p>assumed fixed treatment effect</p></dd>


<dt id="arg-relaxed">relaxed<a class="anchor" aria-label="anchor" href="#arg-relaxed"></a></dt>
<dd><p>relaxed or strict decision rule</p></dd>


<dt id="arg-num-cl">num_cl<a class="anchor" aria-label="anchor" href="#arg-num-cl"></a></dt>
<dd><p>number of clusters used for parallel computing, default: 1</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="value">Value<a class="anchor" aria-label="anchor" href="#value"></a></h2>
    <p>The output of the function is a <code>data.frame</code> object containing the optimization results:</p><dl><dt>Kappa</dt>
<dd><p>optimal threshold value for the decision rule to go to phase III</p></dd>
<dt>n2</dt>
<dd><p>total sample size for phase II; rounded to the next even natural number</p></dd>

<dt>n3</dt>
<dd><p>total sample size for phase III; rounded to the next even natural number</p></dd>

<dt>n</dt>
<dd><p>total sample size in the program; n = n2 + n3</p></dd>

<dt>K</dt>
<dd><p>maximal costs of the program (i.e. the cost constraint, if it is set or the sum K2+K3 if no cost constraint is set)</p></dd>

<dt>pgo</dt>
<dd><p>probability to go to phase III</p></dd>

<dt>sProg</dt>
<dd><p>probability of a successful program</p></dd>
<dt>sProg1</dt>
<dd><p>probability of a successful program with "small" treatment effect in phase III</p></dd>

<dt>sProg2</dt>
<dd><p>probability of a successful program with "medium" treatment effect in phase III</p></dd>

<dt>sProg3</dt>
<dd><p>probability of a successful program with "large" treatment effect in phase III</p></dd>
<dt>K2</dt>
<dd><p>expected costs for phase II</p></dd>

<dt>K3</dt>
<dd><p>expected costs for phase III</p></dd>

</dl><p>and further input parameters. Taking <code>cat(comment())</code> of the
data frame lists the used optimization sequences, start and
finish time of the optimization procedure. The attribute
<code>attr(,"trace")</code> returns the utility values of all parameter
combinations visited during optimization.</p>
    </div>
    <div class="section level2">
    <h2 id="details">Details<a class="anchor" aria-label="anchor" href="#details"></a></h2>
    <p>For this setting, the drug development program is defined to be successful
if it proceeds from phase II to phase III and all endpoints show a
statistically significant treatment effect in phase III. For example, this
situation is found in Alzheimer’s disease trials, where a drug should show
significant results in improving cognition (cognitive endpoint) as well as
in improving activities of daily living (functional endpoint).</p>
<p>The effect size categories small, medium and large are applied to both
endpoints. In order to define an overall effect size from the two individual
effect sizes, the function implements two different combination rules:</p><ul><li><p>A strict rule (<code>relaxed = FALSE</code>) assigning a large overall effect in case
both endpoints show an effect of large size, a small overall effect in
case that at least one of the endpoints shows a small effect, and a medium
overall effect otherwise, and</p></li>
<li><p>A relaxed rule (<code>relaxed = TRUE</code>) assigning a large overall effect if at
least one of the endpoints shows a large effect, a small effect if both
endpoints show a  small effect, and a medium overall effect otherwise.</p></li>
</ul><p>Fast computing is enabled by parallel programming.</p>
<p>Monte Carlo simulations are applied for calculating utility, event count and
other operating characteristics in this setting. Hence, the results are affected
by random uncertainty.</p>
    </div>
    <div class="section level2">
    <h2 id="references">References<a class="anchor" aria-label="anchor" href="#references"></a></h2>
    <p>Meinhard Kieser, Marietta Kirchner, Eva Dölger, Heiko Götte (2018). Optimal planning of phase II/III programs for clinical trials with multiple endpoints</p>
<p>IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available at <a href="https://www.iqwig.de/ueber-uns/methoden/methodenpapier/" class="external-link">https://www.iqwig.de/ueber-uns/methoden/methodenpapier/</a>, assessed last 15.05.19.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-examples">Examples<a class="anchor" aria-label="anchor" href="#ref-examples"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="co"># Activate progress bar (optional)</span></span></span>
<span class="r-in"><span><span class="kw">if</span> <span class="op">(</span><span class="cn">FALSE</span><span class="op">)</span> <span class="fu">progressr</span><span class="fu">::</span><span class="fu"><a href="https://progressr.futureverse.org/reference/handlers.html" class="external-link">handlers</a></span><span class="op">(</span>global <span class="op">=</span> <span class="cn">TRUE</span><span class="op">)</span> <span class="co"># \dontrun{}</span></span></span>
<span class="r-in"><span><span class="co"># Optimize</span></span></span>
<span class="r-in"><span><span class="co"># \donttest{</span></span></span>
<span class="r-in"><span><span class="fu"><a href="https://rdrr.io/r/base/Random.html" class="external-link">set.seed</a></span><span class="op">(</span><span class="fl">123</span><span class="op">)</span> <span class="co"># This function relies on Monte Carlo integration</span></span></span>
<span class="r-in"><span><span class="fu">optimal_multiple_normal</span><span class="op">(</span>Delta1 <span class="op">=</span> <span class="fl">0.75</span>,</span></span>
<span class="r-in"><span>  Delta2 <span class="op">=</span> <span class="fl">0.80</span>, in1<span class="op">=</span><span class="fl">300</span>, in2<span class="op">=</span><span class="fl">600</span>,                   <span class="co"># define assumed true HRs</span></span></span>
<span class="r-in"><span>  sigma1 <span class="op">=</span> <span class="fl">8</span>, sigma2<span class="op">=</span> <span class="fl">12</span>,                            <span class="co"># variances for both endpoints</span></span></span>
<span class="r-in"><span>  n2min <span class="op">=</span> <span class="fl">30</span>, n2max <span class="op">=</span> <span class="fl">90</span>, stepn2 <span class="op">=</span> <span class="fl">10</span>,               <span class="co"># define optimization set for n2</span></span></span>
<span class="r-in"><span>  kappamin <span class="op">=</span> <span class="fl">0.05</span>, kappamax <span class="op">=</span> <span class="fl">0.2</span>, stepkappa <span class="op">=</span> <span class="fl">0.05</span>, <span class="co"># define optimization set for HRgo</span></span></span>
<span class="r-in"><span>  alpha <span class="op">=</span> <span class="fl">0.025</span>, beta <span class="op">=</span> <span class="fl">0.1</span>,                         <span class="co"># planning parameters</span></span></span>
<span class="r-in"><span>  c2 <span class="op">=</span> <span class="fl">0.75</span>, c3 <span class="op">=</span> <span class="fl">1</span>, c02 <span class="op">=</span> <span class="fl">100</span>, c03 <span class="op">=</span> <span class="fl">150</span>,           <span class="co"># fixed/variable costs: phase II/III</span></span></span>
<span class="r-in"><span>  K <span class="op">=</span> <span class="cn">Inf</span>, N <span class="op">=</span> <span class="cn">Inf</span>, S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,                        <span class="co"># set constraints</span></span></span>
<span class="r-in"><span>  steps1 <span class="op">=</span> <span class="fl">0</span>,                                        <span class="co"># define lower boundary for "small"</span></span></span>
<span class="r-in"><span>  stepm1 <span class="op">=</span> <span class="fl">0.5</span>,                                      <span class="co"># "medium"</span></span></span>
<span class="r-in"><span>  stepl1 <span class="op">=</span> <span class="fl">0.8</span>,                                      <span class="co"># and "large" effect size categories</span></span></span>
<span class="r-in"><span>  b1 <span class="op">=</span> <span class="fl">1000</span>, b2 <span class="op">=</span> <span class="fl">2000</span>, b3 <span class="op">=</span> <span class="fl">3000</span>,                   <span class="co"># define expected benefit</span></span></span>
<span class="r-in"><span>  rho <span class="op">=</span> <span class="fl">0.5</span>, relaxed <span class="op">=</span> <span class="cn">TRUE</span>,                         <span class="co"># strict or relaxed rule</span></span></span>
<span class="r-in"><span>  fixed <span class="op">=</span> <span class="cn">TRUE</span>,                                      <span class="co"># treatment effect</span></span></span>
<span class="r-in"><span>  num_cl <span class="op">=</span> <span class="fl">1</span><span class="op">)</span>                                        <span class="co"># parallelized computing</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Optimization result:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Utility: -126.46</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Sample size:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 30, phase III: 29, total: 59</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Probability to go to phase III: 0.37</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Total cost:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 122, phase III: 84, cost constraint: Inf</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Fixed cost:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 100, phase III: 150</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Variable cost per patient:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 0.75, phase III: 1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Effect size categories (expected gains):</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   small: 0 (1000), medium: 0.5 (2000), large: 0.8 (3000)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Success probability: 0.08</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Joint probability of success and observed effect of size ... in phase III:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    small: 0.08, medium: 0, large: 0</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Significance level: 0.025</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Targeted power: 0.9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Decision rule threshold: 0.05 [Kappa] </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Assumed true effects [Delta]: </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    endpoint 1: 0.75, endpoint 2: 0.8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Correlation between endpoints: 0.5</span>
<span class="r-in"><span>  <span class="co"># }</span></span></span>
<span class="r-in"><span></span></span>
</code></pre></div>
    </div>
  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p>Developed by Stella Erdmann, Johannes Cepicka, Marietta Kirchner, Meinhard Kieser, Lukas D. Sauer.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.1.</p>
</div>

    </footer></div>





  </body></html>

